KISUNLA: The NEW Alzheimer's FDA Approved Medication

AVENTURA, Fla. - July 3, 2024 - PRLog -- Are you familiar with Kisunla, the newly FDA-approved medication for Alzheimer's disease?

The Food and Drug Administration approved Eli Lilly's Kisunla (donanemab) earlier this week for mild or early cases of dementia caused by Alzheimer's. It's only the second drug that's been convincingly shown to delay cognitive decline in patients, following last year's approval of a similar drug from Japanese drugmaker Eisai.

Kisunla slowed cognitive decline by up to 35%. It is the first and only amyloid plaque-targeting therapy that uses a treatment regimen based on amyloid plaque removal. Once a month infusion for 30 minutes reduced amyloid plaques on average by 84% which can result in lower treatment costs and fewer infusions.

Neurologists who treat Alzheimer's patients say the approval of Kisunla is an important step after decades of failed experimental treatments.

Dr. Jeff Gelblum, a neurologist at First Choice Neurology and one of the country's leading experts on anti-amyloid treatment for the management of Alzheimer's disease, will summarize this week's exciting approval of Lilly's new anti-Alzheimer medication, Kisunla.

Dr. Gelblum is considered a global thought leader in the neurologic treatment of dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, familial amyloid polyneuropathy, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas.

He maintains numerous research FDA-sponsored affiliations, providing patients immediate access to promising new treatment protocols.

Join Dr. Gelblum on Facebook LIVE (https://www.facebook.com/FCNeurology) for this breakthrough information on Friday, June 5 at 12:30 EDT.

To learn more about Alzheimer's and Dr. Jeff Gelblum, visit First Choice Neurology's website at https://www.fcneurology.net/